Abstract
Midostaurin is a multikinase tyrosine kinase inhibitor acting against targets known to be expressed in hematologic malignancies, especially acute myeloid leukemia. Midostaurin combined with chemotherapy followed by single-agent maintenance therapy elicited statistically significant and clinically meaningful improvement in overall survival versus placebo in patients with newly diagnosed FLT3-mutant acute myeloid leukemia. Although gastrointestinal events were more common with midostaurin, overall the drug was relatively well tolerated. Of note, midostaurin is metabolized by cytochrome P450-3A4 (CYP3A4); therefore, concomitant strong CYP3A4 inhibitors should be used with caution. Preliminary safety results from an ongoing trial evaluating midostaurin as a single agent in the post-transplant setting are encouraging. In addition, studies have evaluated its safety and efficacy in advanced systemic mastocytosis.
Original language | English (US) |
---|---|
Pages (from-to) | 1853-1871 |
Number of pages | 19 |
Journal | Future Oncology |
Volume | 13 |
Issue number | 21 |
DOIs | |
State | Published - Sep 2017 |
Keywords
- FLT3
- PKC412
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplant
- midostaurin
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Oncology
- Cancer Research